Early-life exposure to microbiota restricts colon cancer later in life, study finds

March 13, 2019

ATLANTA--Exposure to microbiota, or microorganisms such as bacteria, in the early stages of life plays a crucial role in establishing optimal conditions in the intestine that inhibit the development of colon cancer in adulthood, according to a study led by Georgia State University.

The research team explored how being exposed to microbiota in utero and in the weeks after birth contributed to the development of colitis-associated cancer in mice later in life. Until now, the effects of prenatal and early postnatal microbial exposure on adult health and disease outcomes have received relatively limited research focus. The findings are published in the journal Cancer Immunology Research.

"Our conclusions are that early-life microbiota are instrumental in regulating proper immune responses that are effective at limiting the development of colon cancer in mice," said Dr. Tim Denning, lead author of the study and professor in the Institute for Biomedical Sciences at Georgia State. "When you have altered microbiota early in life or the absence of microbiota in early life in this case, that may predispose you to the development of colon cancer and perhaps other cancers.

"It's been appreciated for quite some time that the microbiota can play an important role in the development of cancer and other diseases. However, the majority of these studies have been in adults. Our findings show that a key timing of exposure to the microbiota and microbiota metabolites may actually be very early in life. We think this makes sense because during development, whether it's in utero or early postnatal, there are so many changes going on that the contribution of the microbiota can be very impactful. That is the novelty of this finding."

Studies have shown that gut microbiota are instrumental in fostering normal body function and a stable immune system in the host, but the research has been conducted in adult mice and humans because of the difficulty in studying microbiota in utero or in newborns. Humans and mice are initially exposed to microbiota when they are born, either by coming through the birth canal or being delivered through Caesarean section. The mother has microbiota which produce compounds called metabolites that can affect fetal development. In this study, the researchers investigated whether microbiota in this early period could influence disease in adulthood.

The study compared two groups of mice. The first group was mice born to germ-free mothers and raised under germ-free conditions (meaning no exposure to bacteria from their mother or in the environment outside the womb) until weaning. Then, they were transferred to normal conditions and exposed to normal microbiota. The second group was mice born to normal mothers and then bred under regular conditions with microbiota. At six weeks old, all of the mice had colon cancer induced.

"We found remarkable differences," Denning said. "The ex-germ-free mice had much larger and many more tumors in the colon."

The study found the absence of microbiota in early life resulted in enhanced pro-inflammatory gene expression and an accumulation of immune cells called myeloid-derived suppressor cells. These cells suppress other immune cells that can help to limit or kill tumors.

"When you have a tumor that starts to develop, you want your immune system to recognize that as abnormal and try to stop it," Denning said. "If it works perfectly, the tumor is killed off. But the tumor can start to hijack some of those immune cells for its own benefit, and one key example are myeloid-derived suppressor cells. They accumulate inside the tumor and suppress new, incoming immune cells that are trying to kill the tumor. That allows the tumor to grow bigger and for more tumors to grow. That's one of the consequences of the absence of microbiota in early life. To demonstrate this, we blocked a specific pathway that helps to recruit myeloid-derived suppressor cells, and we were able to completely reverse the enhanced size and number of tumors in ex-germ-free mice."

While humans are not germ-free, these results could provide insight into how the composition of microbiota in mothers and babies may control many inflammatory genes and susceptibility to diseases, including cancers, later in life. Gaining a better understanding of how microbiota and other factors are influential very early in life could lead to solutions, such as manipulating certain pathways.
-end-
Co-authors of the study include Drs. Andrew T. Gewirtz, Didier Merlin, Jian-Dong Li, Hirohito Abo, Shingo Matsuyama and Emilie Viennois of the Institute for Biomedical Sciences at Georgia State; Drs. Yoshito Itoh and Yuji Naito of Kyoto Prefectural University of Medicine; Dr. Nicholas Lukacs of the University of Michigan; Dr. Satoru Osuka of Emory University; Dr. Lucie Etienne-Mesmin of the Institute for Biomedical Sciences at Georgia State and Université Clermont Auvergne/INRA; and Dr. Akihito Harusato of the Institute for Biomedical Sciences at Georgia State and Kyoto Prefectural University of Medicine.

The study is funded by the National Institutes of Health, the Crohn's and Colitis Foundation, the Japanese Society for the Promotion of Science and the Veterans Health Administration.

Georgia State University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.